Myriad Genetics, Inc.

MYGN · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders4.0%

Institutions97.0%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30
Total money the company brought in from its core business during the period, before any costs are subtracted.	$824.50M	$837.60M	$753.20M	$678.40M	$690.60M	$638.60M	$851.10M	$772.60M	$771.40M	$753.80M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$247.90M	$252.20M	$236.20M	$202.00M	$197.60M	$186.10M	$201.00M	$177.20M	$145.20M	$132.80M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	$576.60M	$585.40M	–	–	–	–	–	–	–	–
Gross profit as a percentage of revenue.	69.9%	69.9%	–	–	–	–	–	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$387.20M	-$123.50M	-$257.40M	-$140.60M	-$190.50M	-$231.70M	$7.60M	$118.70M	$49.40M	$166.80M
Operating income as a percentage of revenue.	-47.0%	-14.7%	-34.2%	-20.7%	-27.6%	-36.3%	0.9%	15.4%	6.4%	22.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$365.90M	-$127.30M	-$263.30M	$0	$0	-$100000	-$200000	-$200000	-$200000	$125.30M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-1.00	$-3.00	$-1.00	$-0.35	$-2.00	$0.00	$1.00	$0.00	$1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-1.00	$-3.00	$-1.00	$-0.35	$-2.00	$0.00	$1.00	$0.00	$1.00

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30
Cash and highly liquid short-term investments the company can access almost immediately.	$149.60M	$102.40M	$132.10M	$56.90M	$258.40M	$163.70M	$93.20M	$110.90M	$102.40M	$68.50M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$706.60M	$1.03B	$1.15B	$1.20B	$1.32B	$1.40B	$1.56B	$1.17B	$1.22B	$880.50M
All of the company's interest-bearing borrowings, short and long term combined.	$119.90M	$39.60M	$38.50M	–	$0	$4.30M	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$338.60M	$326.50M	$363.30M	$312.90M	$352.90M	$486.40M	$473.80M	$209.20M	$446.60M	$132.40M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$368.00M	$701.10M	$783.20M	$885.80M	$967.80M	$918.20M	$1.09B	$964.90M	$778.20M	$748.10M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$1.80M	-$8.70M	-$110.90M	-$106.30M	$18.20M	$60.70M	$83.70M	$115.90M	$106.20M	$166.30M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	–	–	–	$45.30M	$18.00M	$10.20M	$8.60M	$8.40M	$6.10M	$5.00M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	–	–	–	-$151.60M	$200000	$50.50M	$75.10M	$107.50M	$100.10M	$161.30M

	You	Peer avg
Revenue Growth	-20.8%	+34.0%
ROE	-23.5%	-90.5%

Myriad Genetics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison